Disease Burden of VTE Phases of VTE Treatment.

Slides:

Advertisements

Similar presentations

Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,

Advertisements

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Familial Chylomicronemia Syndrome

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

NOACs for Cancer-Associated Thrombosis:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Starting Strong: Initial Evaluation of the Patient With HCV

NOACs In Long-term VTE Treatment: A State Of The Art Review

Long-Term Treatment of VTE: Case Studies

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

UNDERSTANDING RISK STRATIFICATION IN PAH:

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Case Challenge: Anticoagulant Choices for Acute PE

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

When Would You Use Single Inhaler Triple Therapy in COPD?

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Are We Closer to Personalized Medicine in MS?

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Efficacy and Safety of Edoxaban in Patients With AF and HF

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Oral Anticoagulation in AF

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Real-World Evidence in VTE

Dos and Don’ts for High-Risk Elderly Patients With AF

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Anticoagulation and Thrombosis Management

The Road to Quality Improvement in HER2-Positive Breast Cancer

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

New ELN Recommendations

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Pulmonary Hypertension Updates From 2018

Extraordinary Cases in VTE

How I treat cancer-associated venous thromboembolism

Program Goals Background: Anticoagulation in Patients With VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

At the Crossroads of Coagulation

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Uptitration of Medications in HF: Start Low but Aim High and Stay High

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Extraordinary Cases in Stroke Prevention

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Disease Burden of VTE

Phases of VTE Treatment

Designs of Phase 3 Acute VTE Trials

Risk for Recurrent VTE After Diagnosis

Acute VTE Treatment Trials

Heparin Bridge in NOAC VTE Trials Rationale for Differences in Trial Design?

Prognostic Assessment of Patients With Acute PE

Acute PE Based on Early (Intermediate) Mortality Risk

ESC 2014 PE Anticoagulation Recommendations

NOACs VTE Acute Treatment Trials

Approaches to Managing DVT vs PEa

NOACs in Frail and Elderly Patients

Management of VTE in Cancer Patients

Anticoagulant Treatment of VTE Risk-benefit of NOAC vs VKA

NOACs VTE Extended Treatment Trials

Take-Home Messages

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)